Altered transcription and expression of PTEN in breast tumors: is it regulated by hypermethylation?

Breast cancer (BC) is the commonest cancer in women worldwide with a widely variable incidence between countries and regions. BC is either familial or sporadic. Mutations in tumor suppressor gene, PTEN has been associated with syndromic BC and in a subset of sporadic BCs. The present study was carried out in archival formalin fixed paraffin embedded samples. Immunohistochemistry and quantitative RTPCR indicated a reduced expression/ transcription of PTEN in tumor as compared to adjacent non-tumorous tissue. However, the promoter methylation evaluated by Methylation Specific Restriction Assay indicated that only 20% of the tumors showed PTEN methylation and could not account for the rest of the samples with reduced expression. Overall evidence from literature and our present findings indicate that: (i) Loss of Heterozygosity at PTEN gene locus (ii) germline and somatic gene mutations of PTEN (iii) epigenetic silencing by methylation in PTEN promoter CpG cluster (iv)protein interactions which reduce PTEN transcription and (v) PTEN protein degradation together play an important role in the etiology of BC.

[1]  Tavassoli Manoochehr,et al.  Association of sporadic breast cancer with PTEN/MMAC1/TEP1 promoter hypermethylation , 2011, Medical oncology.

[2]  Q. Hasan,et al.  Regulation of IGF2 transcript and protein expression by altered methylation in breast cancer , 2011, Journal of Cancer Research and Clinical Oncology.

[3]  Michael C. Ostrowski,et al.  Allele-specific tumor spectrum in Pten knockin mice , 2010, Proceedings of the National Academy of Sciences.

[4]  D. Lyon,et al.  Breast cancer in Cowden syndrome: manifestation of a familial cancer syndrome. , 2010, Clinical journal of oncology nursing.

[5]  M. Sireesha,et al.  Relevance of insulin‐like growth factor 2 in the etiopathophysiology of diabetic nephropathy: Possible roles of phosphatase and tensin homolog on chromosome 10 and secreted protein acidic and rich in cysteine as regulators of repair , 2009, Journal of diabetes.

[6]  X. Liu,et al.  DNA methylation profile of tissue-dependent and differentially methylated regions (T-DMRs) in mouse promoter regions demonstrating tissue-specific gene expression. , 2008, Genome research.

[7]  Harry J de Koning,et al.  Breast cancer screening policies in developing countries: a cost-effectiveness analysis for India. , 2008, Journal of the National Cancer Institute.

[8]  C. Eng,et al.  The nuclear affairs of PTEN , 2008, Journal of Cell Science.

[9]  Vivek Aggarwal,et al.  Spectrum of Breast Cancer in Asian Women , 2007, World journal of surgery.

[10]  S. Ponnala,et al.  Dna Methylation in Esophageal Diseases Including Cancer: Special Reference to hMLH1 Gene Promoter Status , 2006, Tumori.

[11]  M. Mori,et al.  Reduced Expression of PTEN Protein and Its Prognostic Implications in Invasive Ductal Carcinoma of the Breast , 2005, Oncology.

[12]  D. Polsky,et al.  PTEN Expression in Melanoma: Relationship with Patient Survival, Bcl-2 Expression, and Proliferation , 2005, Clinical Cancer Research.

[13]  T. Mak,et al.  Dysregulated PTEN‐PKB and negative receptor status in human breast cancer , 2003, International journal of cancer.

[14]  M. Esteller.  CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future , 2002, Oncogene.

[15]  N. Hayward,et al.  Nuclear PTEN expression and clinicopathologic features in a population‐based series of primary cutaneous melanoma , 2002, International journal of cancer.

[16]  S. Cummings,et al.  Serum estradiol level and risk of breast cancer during treatment with raloxifene. , 2002, JAMA.

[17]  Fu-yu Yang,et al.  Variations in Transmembrane Ca2+ Gradient and Apoptosis of Macrophages Induced by Oxidized Low Density Lipoprotein , 2001, Bioscience reports.

[18]  T. Mak,et al.  Regulation of PTEN transcription by p53. , 2001, Molecular cell.

[19]  T. Key,et al.  Epidemiology of breast cancer. , 2001, The Lancet. Oncology.

[20]  G. Viglietto,et al.  PTEN expression is reduced in a subset of sporadic thyroid carcinomas: evidence that PTEN-growth suppressing activity in thyroid cancer cells is mediated by p27kip1 , 2000, Oncogene.

[21]  L. Mulligan,et al.  Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. , 1999, The American journal of pathology.

[22]  Chien-Jen Chen,et al.  PTEN/MMAC1 mutations in hepatocellular carcinomas , 1999, Oncogene.

[23]  H. Feilotter,et al.  Analysis of the 10q23 chromosomal region and the PTEN gene in human sporadic breast carcinoma , 1999, British Journal of Cancer.

[24]  E. Jaffe,et al.  PTEN Gene Alterations in Lymphoid Neoplasms , 1998 .

[25]  H. Hibshoosh,et al.  Allelic loss of chromosome 10q23 is associated with tumor progression in breast carcinomas , 1998, Oncogene.

[26]  R. Vessella,et al.  Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[27]  A. Berchuck,et al.  PTEN/MMAC1 mutations in endometrial cancers. , 1997, Cancer research.

[28]  R. McLendon,et al.  PTEN gene mutations are seen in high-grade but not in low-grade gliomas. , 1997, Cancer research.

[29]  Kathleen R. Cho,et al.  Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. , 1997, Cancer research.

[30]  J. Boyd,et al.  Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas. , 1997, Cancer research.

[31]  W. K. Alfred Yung,et al.  Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers , 1997, Nature Genetics.

[32]  M. Wigler,et al.  PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.

[33]  W. Thompson,et al.  The genetic attributable risk of breast and ovarian cancer , 1996, Cancer.

[34]  J. Struewing,et al.  BRCA1 mutations in young women with breast cancer , 1996, The Lancet.

[35]  H. Cedar,et al.  Role of DNA methylation in the regulation of transcription. , 1994, Current opinion in genetics & development.

[36]  D. Easton,et al.  Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. , 1993, American journal of human genetics.

[37]  R Chopra,et al.  The Indian Scene , 1955, Oryx.

[38]  M. Srinivasulu,et al.  Role of BRCA1, HSD17B1 and HSD17B2 methylation in breast cancer tissue. , 2009, Cancer biomarkers : section A of Disease markers.

[39]  Shi-Nae Lee,et al.  Loss of PTEN Expression in Breast Cancers , 2005 .

[40]  Soma Das,et al.  PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma , 2001, International journal of cancer.